ArticleClinical rheumatology2025
The relevance of complement levels in assessing the activity of lupus nephritis of different pathological types.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application Value of Blood Routine-Derived Indices for the Evaluation of Disease Activity in Systemic Lupus Erythematosus.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSystemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease that predominantly affects women of childbearing age. Lupus nephritis (LN) is a relatively common and serious complication in clinical patients. The aim of this study was to evaluate the correlation of complement levels and SLEDAI- 2000 (SLEDAI- 2 K) with renal activity in different pathological types of LN.
methodsA total of 220 patients with SLE and LN were included. Renal active inflammation was calculated using the National Institutes of Health (NIH) Activity Index (AI) . Patients were classified into two groups based on the AI at the time of kidney biopsy: low-to-moderate-activity group with an AI < 10 and high-active group with an AI ≥ 10. Laboratory indicators, including complement levels and the SLEDAI- 2 K, were collected to assess their correlation with renal activity in LN.
resultsThe average complement levels in class V LN were higher than that in class III/IV and III/IV + V LN. Serum creatinine and 24-h urine protein were lower than those in class III/IV and III/IV + V LN. Laboratory indicators, including complement levels and SLEDAI- 2 K, shown no correlation with AI in class V LN. Appropriate clinical indicators of AI in patients with class III/IV and III/IV + V LN were further assessed by ROC curves, SLEDAI- 2 K exhibiting the highest performance (AUC 0.757, 95% CI 0.687-0.817), 24-h urine protein (AUC 0.736, 95% CI 0.665-0.798), hemoglobin (AUC 0.726, 95% CI 0.655-0.789), C3 (AUC 0.676, 95% CI 0.603-0.744), serum creatinine (AUC 0.664, 95% CI 0.591-0.733), and C4 (AUC 0.660, 95% CI 0.586-0.729).
conclusionDecreased levels of complement C3 and C4 have limited predictive value as a clinical tool for assessing disease activity in patients with LN, especially in class V LN. SLEDAI- 2 K, a widely used clinical scale, correlates with disease activity in patients with class III/IV, III/IV + V LN. Serum creatinine is a clinical indicator of chronic kidney damage in patients with class III/IV, III/IV + V, and V LN. Key Points Complement levels: can they accurately assess disease activity in lupus nephritis? • Studies investigating the correlation between complement levels and disease activity in patients with SLE and LN yield inconsistent results, and the ambiguity of these findings may stem from factors such as the pathological staging of LN and individual variations in complement levels. Fewer studies in the current research on disease activity in patients with LN will be based on different pathological types of LN, which leads to limitations in the final findings. • This study aimed to analyze the feasibility of complement levels and SLEDAI- 2 K in assessing renal activity in patients with different pathological types of LN. • We assessed disease activity by obtaining AI from renal biopsies in 220 patients with LN and examined their correlation with disease activity through the collection of laboratory indicators from these patients. • Decreased levels of complement C3 and C4 have limited predictive value as a clinical tool for assessing disease activity in patients with LN, especially in patients with class V LN.
Indexed as
Identifiers
40192999What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.